Undruggble to Druggable

RaviRas Therapeutics

Our goal is to develop a novel small molecule allosteric binding region inhibitor that are selectively targeting specific mutant allele of RAS oncogenes.

Read More

Our Leading Investors

Undruggable to druggable

Targeting and developing a small molecule inhibitor for RAS mutated cancers

RAS is one of the most frequently mutated oncogenes in human cancer. Mutation in the RAS (KRAS, NRAS, HRAS) oncogene are present in approximately 30% of all human cancers driving tumor cell growth and metastasis by aberrant activation of RAS mediated signaling. We are targeting KRAS in difficult to treat cancers including lung, colon, pancreatic, and NRAS in melanoma, lung, acute myeloid leukemia and myeloma. KRAS inhibitors have been developed to target the specific KRAS G12C mutation, but these therapies are limited to only around 8-10% of KRAS mutant-driven cancers. We are developing a small molecule inhibitor that targets previously “undruggable” mutant RAS including KRAS (G12D, G12C, G12V) and NRAS (61QR, Q61L, Q61K, Q61H, G12D).

RAS mutations are also prevalent in 10–30% of myeloid malignancies and particularly NRAS (G12D, G13D, Q61X) mutations are frequent in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myelomonocytic leukemia (CMML).

There are currently no approved targeted drugs to mutant NRAS, albeit a few in preclinical development.

Read More

RaviRas therapeutics is a drug discovery and drug development LLC biopharma company mainly focusing on the most prevalent target, RAS, in solid and blood cancer models. Our goal is to develop novel small molecule allosteric binding region inhibitors that are selectively targeting specific mutant alleles of RAS oncogenes. The RaviRas therapeutics drug discovery team has extensive small molecule drug development expertise and substantial research experience in the RAS target biology. RaviRas therapeutics office is based in Boston, MA, a hotbed of Pharma drug development.

About Us

RaviRas Therapeutics

About Us
About Us

RaviRas Therapeutics

RaviRas therapeutics is a drug discovery and drug development LLC biopharma company mainly focusing on the most prevalent target in solid and blood cancer model. Our goal is to develop a novel small molecule allosteric binding region inhibitor that are selectively targeting specific mutant allele of RAS oncogenes. The RaviRas therapeutics drug discovery team has extensive small molecule drug development expertise and substantial research experience in the RAS target biology. RaviRas therapeutics office is in Boston, MA

About Us
Get started now

Our Pipeline

Although KRAS G12C specific inhibitors have been approved but there are a large number of patients harboring mutations with KRAS G12D, G12V cancers are still undruggable. Despite the approval of KRAS G12C inhibitors, there remains a large patient population that may benefit from inhibition of other RAS mutations, particularly KRAS G12D and KRAS G12V which are highly prevalent in cancers of the colon, pancreas and lung.

View More
Get started now

Our Pipeline

Although KRAS G12C specific inhibitors has been approved but there are large number of patients harboring mutation with KRAS G12D, G12V cancers are still undruggable. Despite the approval of KRASG12C inhibitors, there remain a large patient population that may benefit from inhibition of other RAS mutations, particularly KRASG12D and KRASG12V which are highly prevalent in cancers of the colon, pancreas and lung.

View More
Targeting addicted KRAS and NRAS

Our Approach

RaviRas therapeutics integrated approach combines deep chemical, structural biology and cancer pharmacology expertise’s in drug discovery to enable the creation of small molecules tailored to unconventional binding sites (switch I and switch II region). Based on clinical data suggesting that genetic drivers and adaptive resistance mechanisms in cancer, we will deploy precision medicine approaches to inform innovative monotherapy and combination regimens.

Read More

Our Specialities

Lung Cancer

Lung Cancer

Colon Cancer

Colon Cancer

Pancreatic Cancer

Pancreatic Cancer

Melanoma

Melanoma

Acute Myeloid

Acute Myeloid

How Does The Process Work?

1

Title Goes Here

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s.
2

Title Goes Here

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s.
3

Title Goes Here

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s.
Start Your Journey

What Our Clients Say

More than 250 five-star reviews on Google
5/5

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s

5/5

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s

5/5

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s

5/5

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s

Want To Join? Request a call now

Research collaborations and investors: RaviRas therapeutics also accepts proposals for preclinical research collaborations and investors, please reach out to us at [email protected]

Request a Call
0 +

Therapists

20 +

Specialties

10 +

Drug Development

0 +

Investors

From The Blog

Got a question?

Frequently Asked Questions

The European languages are members of the same family. Their separate existence is a myth. For science, music, sport, etc, Europe uses the same vocabulary. The languages only differ in their grammar, their pronunciation and their most common words. Everyone realizes why a new common language would be desirable: one could refuse to pay expensive translators.
To achieve this, it would be necessary to have uniform grammar, pronunciation and more common words. If several languages coalesce, the grammar of the resulting language is more simple and regular than that of the individual languages. The new common language will be more simple and regular than the existing European languages. It will be as simple as Occidental; in fact, it will be Occidental.
To an English person, it will seem like simplified English, as a skeptical Cambridge friend of mine told me what Occidental is.The European languages are members of the same family. Their separate existence is a myth. For science, music, sport, etc, Europe uses the same vocabulary. The languages only differ in their grammar, their pronunciation and their most common words.
The European languages are members of the same family. Their separate existence is a myth. For science, music, sport, etc, Europe uses the same vocabulary. The languages only differ in their grammar, their pronunciation and their most common words.
To achieve this, it would be necessary to have uniform grammar, pronunciation and more common words. If several languages coalesce, the grammar of the resulting language is more simple and regular than that of the individual languages. The new common language will be more simple and regular than the existing European languages. It will be as simple as Occidental; in fact, it will be Occidental. To an English person, it will seem like simplified English, as a skeptical Cambridge friend of mine told me what Occidental is.